BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Apr 29, 2025 • 12min
London based Baseimmune shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will use its AI platform to discover and develop new vaccines
Co-founder & CEO Joshua Blight talks about Baseimmune's platform, which was inspired by the work that happened during COVID both in the UK and abroad. The company's current focus is on COVID and malaria.
Apr 29, 2025 • 11min
Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases
Recently named CEO Serge Messerlian, who was previously CEO of Teon Therapeutics and President of Janssen Oncology, describes the platform behind this deal, which came with an upfront payment/investment of $13 million.
Apr 29, 2025 • 12min
London based Laverock shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will be doing its work on programmable gene silencing
CEO David Venables describes Laverock's platform that repurposed miRNA to reprogram cells in a highly specific way. It's own lead programs will be in oncology and regenerative medicine.
Apr 29, 2025 • 10min
The London BioScience Innovation Centre (LBIC) today launched its new Apex Building lab space facility for biotech companies in the heart of the Kings Cross Knowledge Quarter
Dr. Rich Ferrie gives BiotechTV a preview of the new facilities and describes how it is aimed for growing companies that have already achieved a series A or B. It has started at 37% occupancy on launch day.
Apr 25, 2025 • 19min
Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies
CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.
Apr 25, 2025 • 29min
Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is heterogenous in how they are affected by the disease. Plus, a description of Epicrispr's epigenome approach to science, and her personal relationship to facioscapulohumeral muscular dystrophy.
Apr 23, 2025 • 18min
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.
Apr 23, 2025 • 24min
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues in the obesity space today.
Apr 17, 2025 • 17min
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silent will allow Arcus to succeed in TIGIT where others have failed, and a CD73 program that is enrolling very quickly in pancreatic cancer.
Apr 16, 2025 • 13min
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research circles. Plus, his take on what regulatory reforms could help U.S. competitiveness, and areas of research that excite him today.
